Cas No.: | 1207360-89-1 |
Chemical Name: | N-Ethyl-N'-[4-[5,6,7,8-tetrahydro-4-[(3S)-3-methyl-4-morpholinyl]-7-(3-oxetanyl)pyrido[3,4-d]pyrimidin-2-yl]phenyl]urea |
Synonyms: | GDC0349,GDC 0349,GDC 0349 |
SMILES: | O=C(NCC)NC(C=C1)=CC=C1C2=NC3=C(CCN(C4COC4)C3)C(N5[C@@H](C)COCC5)=N2 |
Formula: | C24H32N6O3 |
M.Wt: | 452.54928 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | GDC-0349 is a potent and selective ATP-competitive inhibitor of mTOR with Ki of 3.8 nM; >700-fold selectivity over PI3Kα and other 266 kinases.GDC-0349 has remarkable selectivity over 266 kinases, including all isoforms of PI3K. GDC-0349 inhibits downstream markers of mTOR, including phospho-4EBP1 and phospho-Akt(S473) in an in vivo PK/PD study in mouse, consistent with an inhibition of both mTORC1 and mTORC2 complexes. GDC-0349 demonstrates pathway modulation and dose-dependent efficacy in mouse xenograft cancer models. When dosed orally once daily in athymic mice in a MCF7-neo/Her2 tumor xenograft model (PI3K mutation), GDC-0349 inhibits tumor growth in a dose-dependent manner. It is also efficacious in other xenograft models, including PC3 (PTEN null) and 786-O (VHL mutant). For the detailed information of GDC-0349, the solubility of GDC-0349 in water, the solubility of GDC-0349 in DMSO, the solubility of GDC-0349 in PBS buffer, the animal experiment (test) of GDC-0349, the cell expriment (test) of GDC-0349, the in vivo, in vitro and clinical trial test of GDC-0349, the EC50, IC50,and affinity,of GDC-0349, For the detailed information of GDC-0349, the solubility of GDC-0349 in water, the solubility of GDC-0349 in DMSO, the solubility of GDC-0349 in PBS buffer, the animal experiment (test) of GDC-0349, the cell expriment (test) of GDC-0349, the in vivo, in vitro and clinical trial test of GDC-0349, the EC50, IC50,and affinity,of GDC-0349, Please contact DC Chemicals. |